The Senate Health, Education, Labor & Pensions Committee today held a hearing examining the administration’s blueprint to lower prescription drug prices. Health and Human Services Secretary Alex Azar testified on steps the agency is taking to implement the blueprint. For example, Azar noted, the Centers for Medicare & Medicaid Services recently unveiled updates to its drug-pricing dashboard and warned Medicare Part D plan sponsors that their contracts with pharmacies should not prevent the pharmacist from telling customers when they can get a better deal on a drug by paying cash; and the Food and Drug Administration also recently began publicly identifying drug companies suspected of blocking access to samples needed to test generic drugs. Among other actions, he said HHS is working to require drug companies to include their list price in their television commercials; give Medicare Part D plans market-based tools to negotiate better deals with drug companies; and “bring negotiation to Medicare Part B.”

Related News Articles

Headline
The Federal Trade Commission and Department of Health and Human Services Feb. 14 requested comments for 60 days on market concentration and contracting…
Headline
The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7 announced several new actions to promote…
Headline
The companies that make the first 10 Medicare Part D drugs selected to participate in the Medicare Drug Price Negotiation Program have agreed to participate in…
Headline
The Food and Drug Administration will accept comments through Nov. 17 on draft guidance for labeling proposed biosimilar and interchangeable biosimilar…
Headline
A new Centers for Medicare & Medicaid Services fact sheet reviews how the agency selected the first 10 Part D drugs to include in the Medicare Drug Price…
Headline
The Department of Health and Human Services announced the first list of Medicare Part D drugs subject to price negotiations, a tenet of the Inflation…